Wang Cun, Cao Ying, Yang Chen, Bernards René, Qin Wenxin
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):690-704. doi: 10.1038/s41575-021-00465-x. Epub 2021 Jun 23.
As the fourth leading cause of cancer-related death in the world, liver cancer poses a major threat to human health. Although a growing number of therapies have been approved for the treatment of hepatocellular carcinoma in the past few years, most of them only provide a limited survival benefit. Therefore, an urgent need exists to identify novel targetable vulnerabilities and powerful drug combinations for the treatment of liver cancer. The advent of functional genetic screening has contributed to the advancement of liver cancer biology, uncovering many novel genes involved in tumorigenesis and cancer progression in a high-throughput manner. In addition, this unbiased screening platform also provides an efficient tool for the exploration of the mechanisms involved in therapy resistance as well as identifying potential targets for therapy. In this Review, we describe how functional screens can help to deepen our understanding of liver cancer and guide the development of new therapeutic strategies.
作为全球癌症相关死亡的第四大原因，肝癌对人类健康构成重大威胁。尽管在过去几年中越来越多的疗法已被批准用于治疗肝细胞癌，但其中大多数仅能提供有限的生存获益。因此，迫切需要确定用于治疗肝癌的新的可靶向弱点和强效药物组合。功能基因组筛选的出现推动了肝癌生物学的发展，以高通量方式揭示了许多参与肿瘤发生和癌症进展的新基因。此外，这个无偏见的筛选平台还为探索治疗耐药机制以及确定潜在治疗靶点提供了一个有效工具。在本综述中，我们描述了功能筛选如何有助于加深我们对肝癌的理解并指导新治疗策略的开发。
